Browsing by Author "Pité, H"
Now showing 1 - 4 of 4
Results Per Page
Sort Options
- Alergia ao DióspiroPublication . Pité, H; Sokolova, A; Bartolomé, B; Carreiro-Martins, P; Prates, S; Leiria-Pinto, PA alergia ao dióspiro é rara, não estando identificados os alergénios envolvidos. Descreve -se o caso de uma doente de 24 anos, com história pessoal de rinite alérgica, sensibilizada a ácaros e a pólen de gramíneas, que refere a ocorrência de dois episódios de início súbito de prurido e edema labial, seguidos de tonturas, dor abdominal e vómitos persistentes, minutos após a ingestão de dióspiro, fruto que anteriormente tolerava. O teste cutâneo por picada com este fruto em natureza foi positivo, bem como o doseamento de IgE específica. No immunoblotting com extracto de dióspiro identificou-se uma banda de 40 kDa. A alergia ao dióspiro pode ser grave. Os resultados obtidos apoiam o diagnóstico de anafilaxia a dióspiro mediada por IgE. A proteína de 40 kDa pode constituir um alergénio major do dióspiro, dado que bandas com pesos moleculares similares foram identificadas em cinco do total dos oito casos documentados na literatura.
- Asthma Management With Breath-Triggered Inhalers: Innovation Through DesignPublication . Morais-Almeida, M; Pité, H; Cardoso, J; Costa, R; Robalo Cordeiro, C; Silva, E; Todo-Bom, A; Vicente, C; Marques, JABackground: Asthma affects the lives of hundred million people around the World. Despite notable progresses in disease management, asthma control remains largely insufficient worldwide, influencing patients' wellbeing and quality of life. Poor patient handling of inhaling devices has been identified as a major persistent problem that significantly reduces inhaled drugs' efficacy and is associated with poor adherence to treatment, impairing clinical results such as asthma control and increasing disease-related costs. We herein review key research and development (R&D) innovation in inhaler devices, highlighting major real-world critical errors in the handling and inhalation technique with current devices and considering potential solutions. Furthermore, we discuss current evidence regarding breath-triggered inhalers (BTI). Main body: The two most common significant problems with inhalers are coordinating actuation and inhalation with pressurized metered-dose inhalers (pMDIs), and the need to inhale forcibly with a dry powder inhaler. BTI R&D plans were designed to overcome these problems. Its newest device k-haler® has several other important features, generating a less forceful aerosol plume than previous pMDIs, with efficient drug delivery and lung deposition, even in patients with low inspiratory flow. The local and systemic bioavailability of fluticasone propionate and formoterol (FP/FORM) administered via k-haler® has been shown to be therapeutically equivalent when administered via the previous FP/FORM pMDI. This device requires very few steps and has been considered easy to use (even at first attempt) and preferred by the patients in a randomized crossover study. In our country, FP/FORM k-haler is available without additional costs compared to FP/FORM pMDI. All devices continue to require education and regular checking of the correct inhalation technique. Conclusion: BTI R&D can bring advantage over current available inhalers, avoiding the two most common identified critical errors in inhalation technique. K-haler® BTI is currently available, without an increased cost, and approved for adolescents and adults with asthma in whom treatment with inhaled combined therapy with long-acting beta2-agonists and corticosteroids is indicated. Its attractive and practical design to facilitate its use has been awarded. K-haler® represents added value through innovation to fulfill actual asthma patient needs, thus with potential relevant impact in asthma management and effective control.
- Dor à Palpação da TiróidePublication . Pité, H; Moitinho, M; Silva, A; Ortigueira, I; Dias, L; Gomes, VA 37-years-old woman, complaining of fever, malaise, myalgia, sore throat and dysphagia lasting for 15 days, had been taking antibiotics and paracetamol for 7 days, without symptoms' improvement. The clinical examination revealed hyperaemic oropharynx and enlarged, painful thyroid. Further exams showed increased analytic inflammatory serum parameters as well as thyrotoxicosis. The thyroid gland had heterogeneous echostructure, with markedly hypoechoic areas and significant capsular oedema as well as decreased radionuclide uptake in the scintigraphy. Both symptoms and imaging improved with paracetamol and ibuprofen. Thyroid gland function normalized in two months. The patient remains in follow-up. This case reports the clinical features of subacute or De Quervain's thyroiditis. The differential medical approach to the patient with painful thyroid palpation is discussed. The diagnosis is essentially clinic, highlighting the importance of a rigorous physical exam. These patients' follow-up is required, considering the clinical and analytic progression.
- Reacção ao Glutamato Monossódico – Avaliação por Prova de Provocação em Ocultação SimplesPublication . Pité, H; Carreiro-Martins, P; Prates, S; Morais-Almeida, MEm 1968 foram descritos sintomas autolimitados que surgiam até 30 minutos após refeição em restaurante chinês. Esta síndrome tem sido atribuída ao consumo de glutamato monossódico (GMS), sendo designada por “complexo de sintomas associado ao GMS”. Foi objectivo deste estudo avaliar a resposta ao GMS em dois adultos com história sugestiva de reacção adversa a este aditivo alimentar. Em ocultação simples, foram administrados oralmente, em jejum e em dias diferentes, placebo ou doses crescentes de GMS, até à dose cumulativa de 5 gramas, sendo a prova considerada positiva caso surgissem pelo menos dois sintomas de vinte descritos na literatura. Apenas a prova com GMS foi positiva num doente, que referiu mal-estar geral, astenia e hipersudorese, na dose máxima. À semelhança de outros estudos, os resultados sugerem que doses elevadas de GMS, administradas sem alimentos, podem provocar sintomas em indivíduos com história suspeita de “complexo de sintomas associado a GMS”.